188 related articles for article (PubMed ID: 20549497)
1. Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients.
Bogman K; Silkey M; Chan SP; Tomlinson B; Weber C
Eur J Clin Pharmacol; 2010 Oct; 66(10):1005-15. PubMed ID: 20549497
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.
Jiang T; Rong Z; Xu Y; Chen B; Xie Y; Chen C; Lu Y; Shen Y; Li H; Sun J; Chen H
Clin Drug Investig; 2013 Jan; 33(1):1-9. PubMed ID: 23179471
[TBL] [Abstract][Full Text] [Related]
3. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.
Yin OQ; Tomlinson B; Chow MS
Clin Pharmacol Ther; 2005 Oct; 78(4):370-7. PubMed ID: 16198656
[TBL] [Abstract][Full Text] [Related]
4. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.
Wang G; Lei HP; Li Z; Tan ZR; Guo D; Fan L; Chen Y; Hu DL; Wang D; Zhou HH
Eur J Clin Pharmacol; 2009 Mar; 65(3):281-5. PubMed ID: 18982321
[TBL] [Abstract][Full Text] [Related]
5. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients.
Yin OQ; Wing YK; Cheung Y; Wang ZJ; Lam SL; Chiu HF; Chow MS
J Clin Psychopharmacol; 2006 Aug; 26(4):367-72. PubMed ID: 16855453
[TBL] [Abstract][Full Text] [Related]
6. The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects.
Bramness JG; Skurtveit S; Gulliksen M; Breilid H; Steen VM; Mørland J
Eur J Clin Pharmacol; 2005 Aug; 61(7):499-506. PubMed ID: 16021435
[TBL] [Abstract][Full Text] [Related]
7. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers.
Wang Y; Zhang H; Meng L; Wang M; Yuan H; Ou N; Zhang H; Li Z; Shi R
Eur J Clin Pharmacol; 2010 Jun; 66(6):563-9. PubMed ID: 20414645
[TBL] [Abstract][Full Text] [Related]
9. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
10. Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism.
Shi HY; Yan J; Zhu WH; Yang GP; Tan ZR; Wu WH; Zhou G; Chen XP; Ouyang DS
Eur J Clin Pharmacol; 2010 Nov; 66(11):1131-6. PubMed ID: 20669013
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.
Wang JH; Liu ZQ; Wang W; Chen XP; Shu Y; He N; Zhou HH
Clin Pharmacol Ther; 2001 Jul; 70(1):42-7. PubMed ID: 11452243
[TBL] [Abstract][Full Text] [Related]
12. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J
Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
[TBL] [Abstract][Full Text] [Related]
13. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers.
Lei HP; Wang G; Wang LS; Ou-yang DS; Chen H; Li Q; Zhang W; Tan ZR; Fan L; He YJ; Zhou HH
Ann Pharmacother; 2009 Apr; 43(4):726-31. PubMed ID: 19299322
[TBL] [Abstract][Full Text] [Related]
14. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.
Hu XP; Xu JM; Hu YM; Mei Q; Xu XH
J Clin Pharm Ther; 2007 Oct; 32(5):517-24. PubMed ID: 17875119
[TBL] [Abstract][Full Text] [Related]
15. Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole.
Cho H; Choi MK; Cho DY; Yeo CW; Jeong HE; Shon JH; Lee JY; Shin JS; Cho M; Kim DY; Shin JG
J Clin Pharmacol; 2012 Jul; 52(7):976-84. PubMed ID: 21593280
[TBL] [Abstract][Full Text] [Related]
16. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers.
Ko JW; Jang IJ; Shin JG; Nam SK; Shin SG; Flockhart DA
Clin Pharmacol Ther; 1999 Jun; 65(6):606-14. PubMed ID: 10391666
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
[TBL] [Abstract][Full Text] [Related]
18. Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects.
Zhang D; Wang X; Yang M; Wang G; Liu H
Xenobiotica; 2011 Jun; 41(6):511-7. PubMed ID: 21521077
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19.
Yu BN; Chen GL; He N; Ouyang DS; Chen XP; Liu ZQ; Zhou HH
Drug Metab Dispos; 2003 Oct; 31(10):1255-9. PubMed ID: 12975335
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans.
Kobayashi K; Morita J; Chiba K; Wanibuchi A; Kimura M; Irie S; Urae A; Ishizaki T
Pharmacogenetics; 2004 Aug; 14(8):549-56. PubMed ID: 15284537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]